Form 4: Director Glenn Gormley Receives Aktis Oncology Options

Director Glenn Gormley was granted 37,866 stock options in Aktis Oncology, Inc. with an exercise price of $18.09.

Summary

• Director Glenn Gormley acquired 37,866 stock options in Aktis Oncology, Inc. (AKTS).
• The options have an exercise price of $18.09 per share.
• The grant date for these derivative securities is April 15, 2026.
• The options are set to expire on April 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the Reporting Person's continuous service to the company.

Future Outlook

The options vest in three equal annual installments starting April 15, 2027, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of key leadership.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director options is consistent with standard corporate governance practices in the U.S. biotech industry.
• The grant size is typical for non-executive director compensation packages in mid-cap oncology firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on April 15, 2027.

Key Dates

Keywords

Aktis Oncology, AKTS, Form 4, Insider Trading, Stock Options, Director Compensation